Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Bill Haddad

8264 posts
Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
Uncategorized

Reata Pharmaceuticals Q1 EPS $(1.16) Beats $(2.10) Estimate

By Bill Haddad
May 6, 6:59 AM
Reata Pharmaceuticals (NASDAQ:RETA) reported quarterly losses of $(1.16) per share which beat the analyst consensus estimate of $(2.10) by 44.76 percent. This is a 21.09 percent increase over losses of $(1.47) per share

RETA

Read More
1 minute read
Uncategorized

Annovis Bio Receives US Patent For Method Of Treating Frontotemporal Dementia And Chronic Traumatic Encephalopathy

By Bill Haddad
May 6, 6:57 AM
Annovis Bio Inc. (NYSE:ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced the U.S. Patent and

ANVS

Read More
1 minute read
Uncategorized

Ur-Energy’s Shirley Basin In Situ Uranium Project Receives All Major Permits Effectively Doubling Licensed And Permitted Production Capacity Of Company

By Bill Haddad
May 6, 6:56 AM
Ur-Energy Inc. (NYSE:URG) (TSX:URE) (the "Company" or "Ur-Energy") is pleased to announce that the State of Wyoming and the EPA have completed their respective reviews of the Shirley Basin In

TSX:URE

Read More
1 minute read
Uncategorized

Tapestry Q3 Adj. EPS $0.51 Beats $0.30 Estimate, Sales $1.27B Beat $1.20B Estimate

By Bill Haddad
May 6, 6:55 AM
Tapestry (NYSE:TPR) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.30 by 70 percent. This is a 288.89 percent increase over losses of $(0.27) per share from the same period

TPR

Read More
1 minute read
Uncategorized

Anheuser-Busch InBev Q1 EPS $0.51 Beats $0.50 Estimate

By Bill Haddad
May 6, 6:54 AM
-Reuters

BUD

Read More
1 minute read
Uncategorized

CF Industries Holdings Q1 EPS $0.70 Beats $0.60 Estimate, Sales $1.05B Miss $1.09B Estimate

By Bill Haddad
May 5, 5:30 PM
CF Industries Holdings (NYSE:CF) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.60 by 16.67 percent. This is a 125.81 percent increase over earnings of $0.31 per share from

CF

Read More
1 minute read
Uncategorized

Citizens Q1 EPS $(0.07), Same YoY

By Bill Haddad
May 5, 4:57 PM
Citizens (NYSE:CIA) reported quarterly losses of $(0.07) per share. This is unchanged from the same period last year.

CIA

Read More
1 minute read
Uncategorized

Rayonier Q1 EPS $0.08 Misses $0.10 Estimate, Sales $191.40M Miss $199.63M Estimate

By Bill Haddad
May 5, 4:56 PM
Rayonier (NYSE:RYN) reported quarterly earnings of $0.08 per share which missed the analyst consensus estimate of $0.10 by 20 percent. The company reported quarterly sales of $191.40 million which missed the analyst

RYN

Read More
2 minute read
Uncategorized

Mercury Systems Late Tuesday Cut FY21 Adj. EPS Guidance From $2.35-$2.42 To $2.35-$2.37 vs $2.40 Est., Cut Sales Guidance From $925M-$945M To $910M-$920M vs $938.64M Est.

By Bill Haddad
May 5, 10:50 AM
Business Outlook This section presents our current expectations and estimates, given current visibility, on our business outlook for the current fiscal quarter and fiscal year 2021. It is possible that

MRCY

Read More
1 minute read
Uncategorized

Roche Receives Emergency Use Authorization In India For Its Investigational Antibody Cocktail Used In Treatment Of COVID-19

By Bill Haddad
May 5, 8:00 AM
-Reuters

RHHBY

Posts navigation

Previous 1 … 816 817 818 … 827 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service